PELICAN-IPC 2015-016/Oncodistinct-003: A Prospective, Multicenter, Open-Label, Randomized, Non-Comparative, Phase II Study of Pembrolizumab in Combination With Neo Adjuvant EC-Paclitaxel Regimen in HER2-Negative Inflammatory Breast Cancer

Inflammatory breast cancer (IBC) is a highly aggressive entity with a poor outcome and relative resistance to treatment. Despite progresses achieved during the last decades, the survival remains significantly lower than non-IBC. Recent clinical trials assessing PD-1/PD-L1 inhibitors showed promising...

Descripción completa

Detalles Bibliográficos
Autores principales: Bertucci, Alexandre, Bertucci, François, Zemmour, Christophe, Lerebours, Florence, Pierga, Jean-Yves, Levy, Christelle, Dalenc, Florence, Grenier, Julien, Petit, Thierry, Berline, Marguerite, Gonçalves, Anthony
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2020
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7732675/
https://www.ncbi.nlm.nih.gov/pubmed/33330051
http://dx.doi.org/10.3389/fonc.2020.575978

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7732675/
https://www.ncbi.nlm.nih.gov/pubmed/33330051
http://dx.doi.org/10.3389/fonc.2020.575978

Ejemplares similares